glp 1 a key to weight management and immune support Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic Loss Drugs Magnesium supplement (as Magnesium Oxide) supports nerve GLP-1 Injections for Medical Weight

Epub 2020 Nov 13

Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management

The standard escalation protocol starts at 0.25 mg/week and progresses through 0.5, 1.0, 1.7, and 2.4 mg/week maintenance doses

Ex-4 significantly reduces neuroinflammation by converting proinflammatory M1 microglia into anti-inflammatory M2 microglia both in vitro and in vivo through the rescue of the expression of Arf and Rho GAP adapter protein 3 (ARAP3)